Lineage Cell Therapeutics, Inc. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - March 16, 2017

Attached files

file filename
EX-32 - EXHIBIT 32 - Lineage Cell Therapeutics, Inc.ex32.htm
EX-31 - EXHIBIT 31 - Lineage Cell Therapeutics, Inc.ex31.htm
EX-21.1 - EXHIBIT 21.1 - Lineage Cell Therapeutics, Inc.ex21_1.htm
EX-10.39 - EXHIBIT 10.39 - Lineage Cell Therapeutics, Inc.ex10_39.htm
EX-10.38 - EXHIBIT 10.38 - Lineage Cell Therapeutics, Inc.ex10_38.htm
10-K - BIOTIME, INC 10-K 12-31-2016 - Lineage Cell Therapeutics, Inc.form10k.htm
Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-2 (Registration Nos. 333-128083 and 333-109442), Form S-3 (Registration Nos. 333-166862, 333-183557, 333-187710, 333-188066, 333-201824, and 333-209000), and Form S-8 (Registration Nos. 333-101651, 333-122844, 333-163396, 333-192531 and 333-205661) and related prospectuses of BioTime, Inc. of our reports dated March 16, 2017, with respect to the consolidated financial statements of the Company and the effectiveness of BioTime, Inc. and Subsidiaries' internal control over financial reporting, which appear in this Annual Report on Form 10-K for the year ended December 31, 2016.

/s/ OUM & CO. LLP

San Francisco, California
March 16, 2017


Lineage Cell Therapeutics, Inc. Reports

Also read